Cargando…
Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
Discontinuation of treatment with monoclonal antibodies (mAb) targeting the Calcitonin Gene-Related Peptide (CGRP) pathway leads to an increase in migraine frequency. We aimed to assess changes in free and total CGRP plasma concentrations after the discontinuation of CGRP(-receptor) mAbs. This prosp...
Autores principales: | Raffaelli, Bianca, Terhart, Maria, Fitzek, Mira Pauline, Lange, Kristin Sophie, Mecklenburg, Jasper, Overeem, Lucas Hendrik, Siebert, Anke, Storch, Elisabeth, Reuter, Uwe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861447/ https://www.ncbi.nlm.nih.gov/pubmed/36678920 http://dx.doi.org/10.3390/pharmaceutics15010293 |
Ejemplares similares
-
Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience
por: Raffaelli, Bianca, et al.
Publicado: (2023) -
Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies
por: Terhart, Maria, et al.
Publicado: (2021) -
Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience
por: Raffaelli, Bianca, et al.
Publicado: (2022) -
Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study
por: Raffaelli, Bianca, et al.
Publicado: (2021) -
Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study
por: Overeem, Lucas Hendrik, et al.
Publicado: (2023)